SSY Group Limited announced on 27 April 2026 that China’s National Medical Products Administration (NMPA) has granted production and registration approvals for two cardiovascular therapies—Diltiazem Hydrochloride for Injection (10 mg) and Propranolol Hydrochloride Injection (5 ml: 5 mg and 2 ml: 2 mg).
The newly approved Diltiazem Hydrochloride for Injection is classified as a type 4 chemical drug and has passed the NMPA’s consistency evaluation. Clinically, the product targets supraventricular tachycardia, intra-operative hypertensive crises, hypertensive emergencies and unstable angina.
Propranolol Hydrochloride Injection, approved under type 3 status and also meeting the consistency evaluation standards, is indicated for controlling supraventricular and ventricular arrhythmias, exertional angina and tachycardia associated with pheochromocytoma (in combination with α-blockers). The injectable formulations build on the company’s February 2026 regulatory clearance for Propranolol Hydrochloride bulk drug, which now serves as the active pharmaceutical ingredient for market-ready preparations.
The Board highlighted that these approvals represent continued progress in the Group’s product pipeline and regulatory milestones, underscoring momentum in cardiovascular treatment offerings. This update was issued as a voluntary disclosure to inform shareholders and potential investors of SSY Group’s latest business developments.
Comments